ELV · Q2 2025 Earnings

Bearish

Elevance Health

Reported July 17, 2025

30-second summary

Elevance cut FY25 adjusted EPS guidance to ~$30 and explicitly said the new outlook "is not based on assumptions of a near-term recovery" — management is no longer pricing in a cyclical bounce in ACA or Medicaid margins. Q2 revenue grew 14.3% to $49.4B but the benefit expense ratio ran at 88.9% with FY guided to ~90%, signaling the cost pressure is structural rather than transitory. The tone shift is the story: management called a second consecutive year of cuts "disappointing," abandoned near-term recovery framing, and declined to offer a 2026 outlook.

Headline numbers

EPS

Q2 FY2025

$8.84

Revenue

Q2 FY2025

$49.40B

+14.3% YoY

Operating margin

Q2 FY2025

4.9%

Key financials

Q2 FY2025

Metric	Q2 FY2025	YoY
Revenue	$49.40B	+14.3%
EPS	$8.84	—
Operating margin	4.9%	—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025

Segment	Q2 FY2025	YoY
Health Benefits	$41.6B	+11.9%
CarelonRx	$10.6B	+21.3%
Carelon Services	$7.4B	+63.7%

Other KPIs

Q2 FY2025

Segment	Q2 FY2025
Medical Membership	45.6 million
Medicare Advantage Membership	2.3 million
Medicaid Membership	8.7 million
Benefit Expense Ratio	88.9%
Operating Expense Ratio	10.1%
Adjusted Operating Margin	5.0%
CarelonRx Adjusted Scripts	83.3 million
Carelon Services Consumers Served	97.3 million

Management tone

The tone is materially more defensive than Elevance's typical posture. Three shifts stand out across this single call (no prior briefs available for multi-quarter arc).

From "managing through the cycle" to "no near-term recovery assumed." Prior framings of ACA and Medicaid pressure as transitory have been abandoned. The anchor quote: "It is not based on assumptions of a near-term recovery." This is the most consequential line in the release — guidance has been re-baselined to a world where elevated morbidity persists, not one where it normalizes by Q4 or early 2026. Investors who were modeling a snap-back should rebuild the back half.

From confident guidance setter to contrite serial revisor. Management explicitly said "revising guidance for the second consecutive year is disappointing" — an unusual acknowledgment of credibility damage rather than the typical explanatory framing. The pairing of this admission with the refusal to provide 2026 color signals that internal visibility on cost trend is genuinely impaired, not just being managed for under-promise/over-deliver.

From strategic offense to narrowed sphere of control. Repeated emphasis that management is "prioritizing factors we can directly influence and which are within our control" — pricing discipline, care management, payment integrity. This is a posture shift from prior calls' confidence in managing external dynamics. The implicit message: morbidity, redetermination spillover, subsidy cliff risk, and Medicaid rate cycles are externalities Elevance now plans around rather than through.

On Medicaid specifically: the phrase "prolonged margin recovery period" replaces prior framing of modest deceleration. States are described as constructive on data sharing but rate cycles will take "a couple of rate cycles" to catch up to true acuity. Management still expects Medicaid margins positive for FY25 and YoY improvement in H2 — but below long-term targets.

Recurring themes management leaned on this quarter:

ACA morbidity deterioration and elevated cost trendsMedicaid rate lag vs. acuity-driven cost increasesFocus on controllable levers: pricing discipline, care management, payment integrityCarillon platform scaling as growth engineStructural cost management and operational disciplineMedicare Advantage stability as offset

Risks management surfaced:

Elevated medical cost trends persisting in ACA and Medicaid 'second half'Medicaid rate recovery lagging current cost levels with 'prolonged' recovery periodMarket-wide morbidity increase in ACA from redetermination and lower effectuation ratesBudget reconciliation bill implications including Medicaid work requirements and more frequent eligibility reviewsScheduled expiration of enhanced marketplace subsidies driving further risk pool deterioration

Q&A highlights

Andrew Mock · Barclays

Delineate ACA pressure between unit cost trends and risk pool shifts; explain how risk adjustment assumptions remain unchanged given higher morbidity.

Three principal factors driving sharper medical trends: (1) Risk pool acuity/mobility from higher healthier member proportion and Medicaid-to-ACA migration (~70% of impact); (2) Elevated utilization in ER, behavioral health, specialty pharmacy, and inappropriate IDR usage (~30% of impact). Risk adjustment unchanged because acuity uptick is market-wide mobility trend, not company-specific membership mix shift.

70% of ACA cost pressure from risk pool acuity and member migration30% of ACA cost pressure from utilization and aggressive coding/IDR tacticsRisk pool acuity largely stabilized post lower effectuation rates in AprilInappropriate IDR usage inflates allowed amounts across entire healthcare system

A.J. Rice · UBS

Size relative impact of ACA versus Medicaid in guidance revision; clarify Medicaid rate outlook; assess feasibility of ACA margin recovery in 2026.

Guidance reduction split slightly more weighted toward ACA than Medicaid. ACA forecast embeds elevated morbidity (stabilized but allowing for Q4 surge from subsidy cliff), with expectations of people using more services before coverage lapses. Medicaid planning for elevated morbidity from enrollment losses; rate discussions constructive with states but morbidity increased cost profile. No new initiatives assumed to bend trend.

Guidance revision weighted slightly more to ACA than MedicaidACA embeds assumption of Q4 utilization surge if subsidies lapseMedicaid rate discussions remain constructive with statesManagement not assuming new initiatives in trend bend for forward guidance

Steven Baxter · Wells Fargo

Addresses concern that Medicaid base period rates are incorrectly set with forward trend underpricing; how to prevent continued underpayment.

Current situation is unusual post-pandemic cycle with significant redetermination and acuity changes. States have been constructive in responding to shared data; rates aligned with original expectations but morbidity increased due to enrollment losses. Data now reaching states faster than historical practice. Expect normalization over couple of rate cycles. Medicaid margins still expected to improve YoY in back half and remain positive for full year, though below long-term targets.

States constructively responsive when presented with real-time acuity dataRate alignment expected to normalize over couple of rate cyclesMedicaid margins expected YoY improvement in H2 despite current pressureFull year Medicaid margins remain positive but below long-term targets

Lisa Gill · J.P. Morgan

Comment on Medicare Advantage trend strength in quarter; provide color on 2026 bid strategy for margin recovery.

MA trend remained elevated but came in line with expectations, consistent with prior guidance. 2026 bid approach remains disciplined with too-early specifics but focused on plan offerings for strong retention and sustainable value. Prioritizing HMO, duals products and specific geographies; leaning into margins. Multiyear strategy focused on marketplace stability.

MA trend came in line with expectations despite elevation2026 bid strategy too early for specifics but disciplined approachFocusing on HMO, duals products and margin recovery in 2026Multiyear MA strategy focused on stability and margin improvement

Lance Wilkes · Bernstein

Detail utilization by category (inpatient, outpatient, etc.) and segment differences; comment on prior period development.

ACA market in midst of broad recalibration with market-wide mobility shift post-Medicaid redetermination. Chief utilization drivers: ER and behavioral health services. ACA members in 2024-25 cohort using ER at nearly 2x rate of commercial group members. Prior period development approximately $40 million for quarter with nothing particular to note.

ACA ER utilization nearly 2 times commercial group member rates in 2024-25 cohortER and behavioral health services principal utilization driversPrior period development of approximately $40 million for quarterMarket-wide mobility shift, not company-specific pricing/risk adjustment issue

What to watch into next quarter

Benefit expense ratio trajectory: Q2 came in at 88.9% against a ~90% FY guide. Watch whether Q3 prints below 90% (signaling stabilization) or above (signaling the cut is again too optimistic, given the explicit Q4 surge assumption already embedded).

Enhanced ACA subsidy resolution: management has embedded a Q4 utilization surge from members consuming services before subsidy expiration. If Congress extends subsidies, that creates an offset; if not, watch whether the embedded Q4 assumption is conservative enough.

Medicaid rate cycle progress: management said rate alignment normalizes over "a couple of rate cycles." Watch state-by-state rate updates in Q3 disclosure — particularly whether the cadence of rate true-ups is accelerating as states ingest fresher acuity data.

Initial 2026 framing: management declined to offer 2026 color, an unusual omission at this stage. The Q3 call is the natural inflection — watch whether they reintroduce a 2026 EPS range, hold the "at least 12% long-term EPS growth" anchor, or extend the visibility blackout.

Carelon Services growth durability: +63.7% YoY at $7.4B revenue. Watch whether this remains the principal growth offset to Health Benefits margin compression — and whether segment operating margins disclose any pressure from rapid scaling.

ACA risk adjustment recoverables: management held risk adjustment assumptions unchanged despite acuity migration. If 2025 risk adjustment settles short of accruals, that becomes a Q4 or early-2026 reserve issue.

Sources

Elevance Health Q2 2025 Earnings Release, SEC filing: https://www.sec.gov/Archives/edgar/data/1156039/000115603925000111/a2q2025elvearningsrelease.htm
Elevance Health Q2 2025 earnings call commentary (extracted)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.